(Bloomberg) -- A new cancer medicine developed by AstraZeneca Plc and Daiichi Sankyo Co. seemed to fall short of investors’ expectations in partial results released early after a data leak at a medical conference. Most Read from BloombergBiden Vows Aid for Gaza, Backs Israel Over Hospital BlastHospital Blast Kills Hundreds as Israel, Hamas Trade BlameStocks Drop, Oil Climbs on Renewed Mideast Risks: Markets WrapUPenn Donors Pile Pressure on School as David Magerman Pulls SupportIsrael Latest: Bi